Quoin Pharmaceuticals (NASDAQ:QNRX) COO Denise Carter Acquires 20,490 Shares

Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) COO Denise Carter purchased 20,490 shares of the firm’s stock in a transaction on Monday, August 31st. The stock was bought at an average price of $4.88 per share, for a total transaction of $99,991.20. Following the acquisition, the chief operating officer owned 37,709 shares in the company, valued at $184,019.92. The trade was a 119.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Quoin Pharmaceuticals Price Performance

Quoin Pharmaceuticals stock opened at $6.51 on Wednesday. The stock’s 50-day moving average is $4.77 and its 200-day moving average is $5.89. The company has a market cap of $13.09 million, a price-to-earnings ratio of -0.26 and a beta of 1.50. Quoin Pharmaceuticals, Ltd. Sponsored ADR has a 12 month low of $3.25 and a 12 month high of $41.80.

Quoin Pharmaceuticals (NASDAQ:QNRX) last announced its quarterly earnings results on Friday, August 14th. The company reported ($1.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.61) by ($0.29). Research analysts anticipate that Quoin Pharmaceuticals, Ltd. Sponsored ADR will post -7.38 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. ThinkEquity started coverage on Quoin Pharmaceuticals in a report on Monday, June 15th. They issued a “buy” rating on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a report on Monday, July 20th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold”.

Hedge Funds Weigh In On Quoin Pharmaceuticals

A number of hedge funds have recently made changes to their positions in QNRX. Simplify Asset Management Inc. bought a new position in shares of Quoin Pharmaceuticals during the 4th quarter worth about $252,000. SummitTX Capital L.P. increased its stake in Quoin Pharmaceuticals by 54.8% in the first quarter. SummitTX Capital L.P. now owns 100,300 shares of the company’s stock valued at $662,000 after acquiring an additional 35,505 shares during the period. ADAR1 Capital Management LLC acquired a new position in Quoin Pharmaceuticals in the fourth quarter worth about $840,000. Boothbay Fund Management LLC acquired a new position in Quoin Pharmaceuticals in the fourth quarter worth about $863,000. Finally, Millennium Management LLC acquired a new position in Quoin Pharmaceuticals in the fourth quarter worth about $1,080,000. Institutional investors and hedge funds own 8.63% of the company’s stock.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.